Gide advises BioMérieux on acquisition of Chinese biomedical company Hybiome

Gide has advised BioMérieux, a world leader in the field of in vitro diagnostics, on its acquisition of a majority stake in Suzhou Hybiome Biomedical Engineering Co., Ltd.

As part of the deal, the French listed company (Euronext Paris: BIM) acquired 54% of the shares in Hybiome for a valuation of EUR 165 million, as well as additional assets such as distribution rights and existing installed base for EUR 25 million. It had already purchased a minority stake in the Suzhou-based company earlier this year in July, a transaction on which Gide also advised.

Founded in 2009, Hybiome specialises in automated immunoassay tests. The company develops, manufactures and sells a complete range of diagnostic solutions (reagents, instruments and software) cleared by the National Medical Products Administration.

Gide’s advice covered all aspects of the transaction, including legal due diligence, structuring, and negotiation and drafting of the transaction documents. Gide also advised on the financing aspects of the transaction.

The Gide team was led by partner Fan Jiannian in Shanghai, with the assistance of associates Han Sufeng, Cao Can and Li Jing.